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Abstract
Sensorimotor dysfunction following incomplete spinal cord injury (iSCI) is often characterized by the debilitating symptoms of
paralysis, spasticity and pain, which require treatment with novel pleiotropic pharmacological agents. Previous in vitro studies
suggest that Albumin (Alb) and Oleic Acid (OA) may play a role together as an endogenous neurotrophic factor. Although Alb
can promote basic recovery of motor function after iSCI, the therapeutic effect of OA or Alb-OA on a known translational
measure of SCI associated with symptoms of spasticity and change in nociception has not been studied. Following T9 spinal
contusion injuryinWistarrats, intrathecaltreatmentwith: i)Saline, ii)Alb (0.4 nanomoles), iii)OA (80 nanomoles), iv)Alb-Elaidic
acid (0.4/80 nanomoles), or v) Alb-OA (0.4/80 nanomoles) were evaluated on basic motor function, temporal summation of
noxious reflex activity, and with a new test of descending modulation of spinal activity below the SCI up to one month after
injury. Albumin, OA and Alb-OA treatment inhibited nociceptive Tibialis Anterior (TA) reflex activity. Moreover Alb-OA
synergistically promoted early recovery of locomotor activity to 50610% of control and promoted de novo phasic descending
inhibition of TA noxious reflex activity to 4765% following non-invasive electrical conditioning stimulation applied above the
iSCI. Spinal L4–L5 immunohistochemistry demonstrated a unique increase in serotonin fibre innervation up to 4.261.1 and
2.360.3 fold within the dorsal and ventral horn respectively with Alb-OA treatment when compared to uninjured tissue, in
addition to a reduction in NR1 NMDA receptor phosphorylation and microglia reactivity. Early recovery of voluntary motor
function accompanied with tonic and de novo phasic descending inhibition of nociceptive TA flexor reflex activity following
Alb-OA treatment, mediated via known endogenous spinal mechanisms of action, suggests a clinical application of this novel
neurotrophic factor for the treatment of paralysis, spasticity and pain.
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Introduction
Many patients develop change in sensorimotor function below
spinal cord injury (SCI), which include debilitating symptoms of
spasticity [1,2] and changes in pain processing at the spinal level
[3–5]. These symptoms may combine to impede the successful
rehabilitation of residual voluntary motor function following
incomplete spinal cord injury (iSCI) [6]. The presence of multiple
spinal pathophysiological mechanisms after SCI [7–10] require that
novel treatments simultaneously modulate neuronal hyperexcitabil-
ity, neuroinflammation and adaptive or maladaptive neuroplasticity
of both segmental and residual descending control systems across
the lesion site [9,11–13]. Indeed the increase in neuronal NMDA
receptor phosphorylation or glutamate receptor upregulation
[14,15], microglial and astrocyte reactivity [15,16] and change in
descending serotoninergic innervation of spinal activity below the
injury [17,18] have been implicated in symptoms of pain, spasticity
and paralysis following iSCI.
Albumin (Alb) is necessary for oleic acid (OA) production by
astrocytes [19] and extracellular Alb and OA are incorporated into
neurons leading to dendritic growth, GAP-43 and microtubule-
associated protein (MAP-2) upregulation in vitro [20]. Moreover Alb
promotes motor recovery of SCI by neuroprotection against glutamate
[21]. While omega-3 fatty acids can promote gain in function [22], no
modulation of sensorimotor activity has been observed with omega-9
such as OA following iSCI [22]. However as Alb contains three
primary specific binding sites for OA [23], the administration of this
serum protein with the omega-9 fatty acid in vivo, either individually or
in combination, may reveal recovery of unidentified specific
sensorimotor function and symptoms following iSCI.
Several clinical studies have identified Tibialis Anterior (TA)
hyperreflexia or flexor reflex function as an indirect marker of
change in spinal nociceptive function [24–26], paralysis [6] and
spasticity[26–28].The measurementof cutaneousnociceptive flexor
reflex activity in animal models is used routinely to assess
pharmacological modulation of spinal excitability [29,30], including
the modulatoryroleof both tonic and phasicdescending modulatory
pathways [31–34]. Although functional plasticity of descending
antinociceptive pathways has not been studied after experimental
SCI, their role has been established in phasic inhibition of lumbar
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conditioning stimulation [34] while dorsolateral funiculus lesion
leads to immediate stretch hyperreflexia [35,36]. As such the
evaluation of both tonic and phasic modulation of nociceptive flexor
reflex activity may provide important information regarding
clinically relevant neuroplasticity within spinal and descending
modulatory systems after iSCI [37–40], and in this study treatment
effects with novel neurotrophic factors such as Alb-OA.
Here we show that local administration of the Alb-OA complex
synergistically promoted tonic inhibition of temporal summation
of TA noxious reflex activity, de novo phasic descending inhibition
of nociceptive reflex activity mediated across the iSCI, and early
motor recovery [41]. In addition Alb-OA strongly increased
lumbar serotoninergic innervation, well above the normal level
observed in animals without SCI, reduced phosphorylation of the
NR1 NMDA receptor and effectively blocked microglia reactivity.
Preclinical development of the Alb-OA complex for the treatment
of cutaneous noxious hyperreflexia, altered spinal nociception,
spasticity and deficit of voluntary motor function following iSCI
will be discussed.
Materials and Methods
Ten week old male Wistar rats, with an approximate weight of
250–300 g, were used in this study and maintained in the animal
resource unit with food and water ad libitum, following approval by
the institutional animal experimentation ethical committee. The
experiments adhered to the guidelines of the Committee
for Research and Ethical Issues of IASP published in Pain
1983;16:109–110, following approval from the Ethical Committee
for Animal Welfare of the ‘‘Hospital Nacional de Paraple ´jicos’’ in
Toledo (2007; PI07-0806). Animals were subjected to spinal cord
injury by moderate T9 contusion. Following SCI, animals were
randomly assigned to five groups, each of which was administered
with an intrathecal bolus of the following: Saline (Sal, 0.9%, n=8),
Albumin (Alb, 0.4 nanomoles, n=8), Oleic Acid (OA, 80
nanomoles, n=8), Albumin-Oleic Acid (Alb-OA, 0.4/80 nano-
moles, n=11) and Albumin-Elaidic Acid (Alb-EA, 0.4/80
nanomoles, n=11). The compounds were administered in a
volume of 10 ml, by the intrathecal route [42], immediately
following the SCI and every 3 days thereafter for a total of 28 days.
A further group of naı ¨ve rats was used as the uninjured control
(n=8), instead of animals with a sham T8 laminectomy because
non-significant changes in central sensitization measured by
Tibialis Anterior (TA) reflex temporal summation have been
identified previously (unpublished data).
Preparation of the Albumin-Oleic acid complex
The dialysis membrane (D0655-100FT, Sigma-Aldrich, Spain)
was prepared by washing it for 4 h under running water under
reduced flow. The membrane was then washed, firstly with 0.3%
(w/v) solution of sodium sulphide at 80uC for 2 minutes, then with
double distilled and deionised water (Milli-Q, Merck) preheated to
60uC for a further 2 minutes, followed with a 0.2% (w/v) solution
of sulphuric acid at ambient temperature. Finally, the membrane
was washed again with double distilled and deionised water and
placed in a receptacle with the same water.
Elliot-Calcium buffer [43] was prepared with the final pH
adjusted to 7.4 and filtered with a 0.22 mm pore size (SCGPT05RE,
Millipore). Before incubation CaCl2.2 H2O was added to prepare
1.3 mM Elliot-Ca buffer. Commercially available lyophilised
bovine albumin (D0655, Sigma-Aldrich, Spain) was then dialysed
by preparing a 10% solution in Elliot-calcium buffer, which was
then placed inside the pre-treated dialysis membrane. The dialysis
was performed in agitation at 4uC, with 3 washes at 12 hours, 18
and 24 hours respectively. Finally bovine albumin was filtered with
a 0.2 mm pore size (4525, Serum AcrodiscH 37 mm syringe filter,
Pall Gelman Laboratory). Aliquots of 1 ml bovine albumin were
prepared and stored at 220uC.
The albumin-oleic acid complex was prepared with 2% (w/v)
bovine albumin solution, by adding oleic acid (O1008, Sigma-
Aldrich, Spain) [20]. An albumin-oleic acid (1:1) solution was
prepared to a concentration of 80 nanomoles in saline (0.9%). The
albumin-elaidic acid complex was similarly prepared to the same
concentration (E4637, Sigma-Aldrich, Spain).
Experimental animal surgery
Wistar rats were anesthetized with pentobarbital (Dolethal,
Ve ´toquinol, 65 mg/kg, i.p., Ref: 737) and xylazine (Xilagesic
10 mg/kg concentration, i.p. Calier, Ref: 25225), followed by a
supplementary 30% dose following aproximately 90 minutes of
experimental surgery. In addition 0.1 ml of antibiotic was
administered (2.5% Baytril, Enrofloxacin, Bayer) after surgery,
followed by daily doses up to 3 days after spinal cord injury.
Commercially available rat intrathecal catheters (ALZT7740Z,
Charles River Laboratories, Spain) were implanted (see below) and
externalized accordingly [42]. Immediately before surgical im-
plantation, the catheter was re-sterilised with absolute ethanol, and
thoroughly washed with sterile 0.9% saline. Following skin incision
and blunt dissection of the muscle layers overlying the vertebrae, a
small hemi-laminectomy at the vertebral T10 level was performed
(spinal T9). The exposed T9 dura was subjected to a small
durectomy with iris-type scissors so that the tip of the intrathecal
catheter could be inserted rostrally and medially on top of the
spinal cord with a final position just below the intended T9
contusion site. The area was cleaned to permit catheter fixture
with acrylate cement to the T11 vertebrae. The percutaneous end
of the intrathecal catheter was finally secured by inserting it
through a small cutaneous incision at the base of the cranium,
whereupon it was filled with 0.9% sterile saline and tapped with a
custom-made nylon filament.
Following intrathecal catheter implantation a spinal T9
contusion was performed [44]. A bilateral T9 vertebral laminec-
tomy enabled spinal contusion by allowing an 11-gram weight to
fall from a height of 12 mm onto a cylindrical flat-tipped impactor
with a 2.5 mm diameter placed centrally over the exposed spinal
cord above the intact dura. Once the contusion was performed,
artificial dura mater (Neuropatch, Ref: 106403, B. Braun), the
overlying muscle layers were reapposed with a continuous suture
stitch and the skin was finally closed with a subdermal suture, both
with a 4-0 reabsorbable thread. Rats were carefully observed
during recovery, and the bladder was manually expressed daily
until recovery of function.
Behavioural analysis of evoked voluntary motor function
Evoked voluntary motor function before and after T9 contusion
injury wasanalyzed inallexperimentalgroups with theRotarodtest
(4600, Ugo Basile), instead of the standard BBB test [45], because of
thespecificneed todocumentearlythe maximalevokedcapacityfor
generalised hindlimb-forelimb locomotor function after SCI. Prior
to contusion injury, each animal was trained for three days to
remainupon a cylindrical surface whichrotatedat 5 rpm for at least
5 minutes [46]. On the day before SCI control data were obtained
by subjecting the rats to the Rotarod test, but with the cylinder
rotating at a steadilyaccelerating speed from 5 to 15 rpmduringthe
5 minute test duration [46]. Following SCI rats were tested on day 4
and then weekly thereafter up to 28 days to document general
motor recovery and the effect of the different treatments.
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Four weeks after spinal cord injury, the rats were rapidly
anesthetised with isoflurane (2%) in medicinal air (17% oxygen, at
2 l/min, Synthetic medical air, Ref: X505, Carburos Metallicos) for
neurophysiological analysis of nociceptive Tibialis Anterior spinal
reflex activity. The nose was then inserted into a plexiglass adapter
(Cibertec, S.A.) so that the isoflurane-air mixture (2.0%, 1 l/min)
could be administered directly, followed by the subcutaneous
injection of atropine. The animal was placed in a supine position on
an electric blanket maintained at 37uC (RTC1 Thermal Regulator,
Cibertec S.A.). Hair over the leftTA muscle and at the mid-thoracic
level was removed and both the trunk and the hindlimbs were
extended and fixed into a neutral position with adhesive tape during
the entire experiment. Bipolar electromyographic responses were
recorded by subcutaneaously inserting two multi-stranded TeflonH-
coated steel electrodes (Cooner Wire, USA) 0.5 cm into the belly of
the Tibialis anterior (TA) muscle of the left limb. In addition, two
platinum subdermal electrodes (Ref. E2, Astro-Med Inc., Grass
Instruments, USA) were inserted into the tip of the fourth toe and
secured with adhesive tape. Lastly, an earth electrode was inserted
subcutaneously between thestimulation electrode and the recording
electrode at the level of the left ankle.
Prior to beginning reflex EMG measurements, the isoflurane
anaesthesia level was lowered to 1.2% MAC in medicinal air (1 l/
min). The evoked electromyographic responses of the TA muscle
were recorded at a gain of 2K, with a bandwidth filter of between
30 Hz – 10 KHz using a differential AC amplifier (AE3, Cibertec
S.A.). The electrical stimulus was applied via a stimulation isolation
unit (ISU 165, Cibertec S.A.) from an analogue stimulator
(CS20BP, Cibertec S.A.), presented as pulses of 2.0 ms duration.
Reflex threshold was identified by characterising the minimal
current intensity (mA) required to evoke a clear nociceptive TA
reflex EMG response between 0.2 and 1.0 s after stimulation, in
over half of ten stimuli. Nociceptive TA reflex activity and temporal
summation was evoked during a train of 16 stimuli applied at 1 Hz.
The role of descending inhibitory pathways across the T9 spinal
cord injury upon nociceptive TA reflex activity was assessed
indirectly by applying a percutaneous high frequency electrical
conditioning stimulus across the T6-7 vertebral level, by applying
an electrical stimulation protocol that has previously been
employed to modulate C-fibre evoked potentials [47]. Two
platinum subdermal needle electrodes (Ref: E2, Astro-Med INC.
Grass, USA) were inserted into each side of the trunk at the T6-7
vertebral level, in order to deliver a stimulus just above the level of
the T9 experimental contusion. The high frequency conditioning
protocol consisted of a 1 s 100 Hz train, with pulse duration of
0.1 ms, applied every 10 s during a total period of 15 minutes.
One minute immediately following the mid-thoracic electrical
conditioning stimulation, nociceptive TA reflex activity was
recorded using the protocol described above. Similar conditioning
electrical stimulation applied to forelimb nerves have been shown
to mediate long-lasting inhibition of nociceptive cutaneous spinal
reflex activity via a noradrenergic sensitive mechanism [34].
Data were collected with an analog-digital converter (CED
Micro 1401 MkII A/D, CED, UK) with data collected at 20 KHz
sampling rate. Electromyographic data were integrated using the
modulus function of the analysis software (Spike 2, CED, UK)
between 0.2 and 0.6 s after the stimulus. Integrated reflex EMG
data were analyzed after each stimulus and also grouped for the
first and second phase of temporal summation in light of published
evidence suggesting that modulation of spinal excitability via
descending pathways is evident after a few stimuli [31].
T9 SCI contusion volume analysis and lumbar L4–L5
immunohistochemistry
At 30 days after SCI, animals were euthanized with sodium
pentobarbital followed by intracardiac perfusion with saline and 4%
paraformaldehyde in 0.1 M phosphate buffer (PB). The extracted
spinal tissue was transferred to 30% sucrose in 0.1 M phosphate buffer
a n dk e p ta t4 uC for at least two days to provide cryoprotection.
Both T6-T13 and lumbar L4–L5 tissue were cut at 30 mmi na
Leica CM1900 cryostat and preserved at 230uC until use. Serial
sections were collected on slides at a distance of 210 mm between
consecutive sections. Thoracic tissue were prepared with Van
Gieson’s stain and the volume of the spared tissue was calculated
with Cavalieri’s method for volume estimation (see below). For
immunohistochemical analysis sections were preincubated for 1 h
in a blocking solution composed of 5% normal goat serum (NGS,
Vector) and 0.2% Triton X-100 (Merck) diluted in 0.1 M PB in
saline. After the general blocking steps, sections were incubated
overnight at 4uC with rabbit primary antibodies against serotonin
(rabbit anti-5HT, 1:4000, Ref: S5545, Sigma-Aldrich) or microglia
(Mouse, anti-CD11b clone OX-42, 1:5000, Ref: Ab1211-100,
Abcam). Blocking for nonspecific background staining for pNR1
expression analysis was performed by incubating with a protein
block serum (Ultra-V-Block, Ref. TA-125-UV, Thermo Scientific)
for 5 minutes at room temperature, prior to overnight incubation
with the primary antibody at 4uC (rabbit anti-pNR1, Ser 897
phosphorylated, 1:1000 Ref: DAM1475052; Millipore).
Following primary antibody incubation, the tissue was washed
three times in 1% NGS (except for pNR1 where PBS was used)
and then incubated with the appropriate secondary antibody
conjugated with Alexa Fluor 594 (1:1000; 1 hour 4uC; anti-rabbit,
Ref: A11012, Invitrogen) or Alexa Fluor 488 (1:1000; 1 hour 4uC;
anti-mouse, Ref: A11012, Invitrogen). The sections were then
mounted with Fluoromount (Ref F4680, Sigma-Aldrich) and
coverslips for the preservation of fluorescence-stained slide tissue
(Thermo Scientific Superfrost Ultra Plus, Ref: J3800AMNZ) and
analyzed with a fluorescent microscopy.
Image acquisition and analysis
Spinal cord volume of the injured region was calculated by
Cavallieri’s method for volume estimation [48] using Newcast
image analysis software (Visiopharm Integrator Software, Visio-
pharm). Images of injured and uninjured spinal cords were
visualized with VIS in an Olympus BX61 microscope with a DP71
digital camera. Data are expressed as mm
3 of tissue referred to a
1 mm slice of spinal cord.
For immunohistochemical spinal cord tissue analysis, digital
images of the tissue were obtained with a confocal microscope
(Leica SP5, Leica) and processed with NIHImage J software (Image
J 1.38x, NIH). For each antibody, measurements were carried out
over 10–20 images (minimum of 3 images/section/animal; n=6–7
rats per group) which were sampled from digital images of the tissue
obtained with a Leica DFC350 FX camera attached to a DM5000
B Leica epifluorescence microscope. Microscope illumination and
data acquisition settings were fixed throughout the entire analysis
procedure for each specific analysis.
To maintain a constant detection threshold for each image and to
compensate for subtle variability of the immunostaining procedure
between sections, only immunoreactive 5HT innervation density and
number of cells that expressed pNR1 were analysed if the image was
at least 50% darker than the average grey level after background
subtraction, and shading correction were performed in the areas of
grey matter. General 5-HT analysis was performed for the dorsal and
ventral horn, while OX-42 area and number of pNR1-positive cells
were analyzed specifically within laminae I-II and the IV–VI (with
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The OX-42 analysis protocol was performed as previously published
[49]. The immunoreactive 5-HT and OX-42 density in addition to
the number of cells expessing pNR1 were averaged and presented as
group data. The quantification was presented for 5-HT innervation
and OX-42 density as the area in mm
2, in addition to the number of
cells which positively expressed p-NR1 within the dorsal horn. All
analytical procedures were performed blind, without knowledge of
the experimental conditions.
Statistical tests
Data were analyzed using a one-way ANOVA for comparisons
between groups, while a two-way ANOVA was used for longitudinal
analysis such as with the rotarod tests, or for analysis of the temporal
summation of TA nociceptive reflex activity. Post-hoc tests were
performed with the Students t test (rotarod analysis), the Tukey post-
hoc test (electrophysiological data) and the Bonferroni test
(immunohistochemistry, Graphpad Prism 4.00, USA).
Results
Allexperimental groupsdemonstrated anincreaseinbodyweight
during the 28 day study following moderate T9 contusion SCI,
suggesting that none of the pharmaceutical treatments were
associated with poor health and or adverse drug reactions. Animals
treated with saline revealed an increase of 22.965.6% body weight
during the one month SCI period, while albumin alone
(49.964.8%) and oleic acid alone (48.662.5%) applied via the
intrathecal route significantly potentiated weight gain compared to
saline alone (p,0.05). Animals treated with albumin-oleic acid also
revealed an increase in body weight (39.964.6%).
Synergistic early recovery of evoked motor function after
iSCI with Alb-OA
Four days after T9 contusion SCI in animals treated with saline
evoked voluntary motor function as assessed on the rotarod was
reduced to 1.060.1% when compared to the pre-lesion control
value (100.062.4%, Fig. 1A). Two-way repeated measures
ANOVA revealed a difference in recovery rate of voluntary
motor function between all experimental groups with different
treatments (F=17.7; d.f.=4,3; p,0.001). The experimental SCI
group treated with albumin-oleic acid demonstrated the greatest
recovery of voluntary movement to 50.0614.8% at 28 days
compared to the saline-treated control group (F=8.96, d.f.=1,
p,0.01). However animals treated with albumin alone also
revealed recovery of motor function up to 28 days after SCI to
34.9610.3%, when compared to the control group (F=5.6,
d.f.=1, p,0.05).
The effect of albumin-oleic acid upon evoked voluntary motor
function was also evident during acute SCI (Fig. 1B). When all
data were analyzed between 4–14 and 21–28 days after SCI an
early synergistic effect of albumin-oleic acid on motor function
recovery was evident. Specifically, motor function measured from
4–14 days after SCI with saline treatment was reduced to
2.460.6%, but was significantly potentiated to 3467% following
albumin-oleic acid treatment (Fig. 1B, unpaired two-tailed t-test,
t=4.63; d.f.=4; p,0.01). Treatment with albumin or oleic acid
alone during the acute phase of SCI failed to promote significant
motor recovery. The early effect of albumin-oleic acid treatment
was maintained during the sub-acute phase of SCI from 21 to 28
days (Fig. 1B). Specifically animals treated with albumin-oleic acid
recovered up to 50610% of the pre-lesion control level of motor
activity compared to the saline-treated group (t=25.8; d.f.=2;
p,0.01), while the group treated with albumin also revealed a
modest recovery to 3267% (t=6.5; d.f.=2; p,0.05).
Tonic inhibition of TA reflex activity with Alb, OA and
Alb-OA treatment after iSCI
Rectified TA reflex EMG activity recorded in response to 16
noxious electrical stimuli was present in naı ¨ve (Fig. 2A) and animals
with experimental T9 contusion SCI with different treatments
(Fig. 2B–2F), illustrating a strong inhibitory effect with albumin
(Fig. 2C) or Alb-OA alone (Fig. 2F) on temporal summation.
Figure 1. Albumin-Oleic Acid (Alb-OA) Synergistically Promotes Early Recovery of Motor Function following T9 Spinal Cord Injury.
Longitudinal analysis of the mean time spent on the rotarod following contusion (Cont) SCI from 4 to 28 days revealed that intrathecal administration
of both Alb (0.4 nanomoles, p,0.05) and Alb-OA (80 nanomoles, p,0.01) promoted better motor recovery, compared to the spinal contusion group
treated with saline (Sal) alone (Fig. 1A). Treatment with OA (80 nanomoles) alone or Alb-Elaidic acid (Alb-EA, 0.4/80 nanomoles) failed to potentiate
locomotor recovery (Fig. 1A). Analysis of voluntary motor function during the early (4–14 day) and subacute (21–28 day) period of contusion SCI
demonstrated that Alb-OA (0.4/80 nanomoles) synergistically promoted functional recovery soon after contusion injury when compared to animals
treated with saline (Sal) alone, while Alb treatment enhanced the time spent on the rotarod specifically during the late phase (Fig. 1B). Statistical
analysis was performed with a two-way (Fig. 1A) and one-way ANOVA (Fig. 1B), supported by a post-hoc Bonferronni test for each experimental
group compared with animals with SCI treated with Sal alone (* - p,0.05; ** - p,0.01).
doi:10.1371/journal.pone.0026107.g001
Albumin-Oleic Acid Treatment of Spinal Cord Injury
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26107Figure 2. Inhibition of Tibialis Anterior Reflex Activity with Albumin, Oleic Acid and Albumin-Oleic Acid after SCI. Qualitative analysis
of rectified nociceptive Tibialis Anterior (TA) noxious reflex temporal summation at 28 days following spinal contusion (Cont, Fig. 2A–2F, scale bar
20 mV/2.5 s) supported the quantification of reflex inhibition (Fig. 2H) with either albumin (Alb, 0.4 nanomoles, p,0.001), oleic acid (OA, 80
nanomoles, p,0.001) or the complex Alb-OA (0.4/80 nanomoles, p,0.001) when compared to animals with SCI treated with saline alone (Sal).
Importantly noxious TA reflex activity following moderate T9 contusion injury was not different for either the averaged response calculated from the
second to seventh stimulus (Fig. 2G) or the first reflex response (Fig. 2G inset, same format) amongst the experimental treatment groups when
compared to the responses observed in naı ¨ve animals or with SCI treated with saline alone. Although no increase in temporal summation for the first
to the sixteenth reflex response was identified following contusion SCI (Fig. 2H), significant inhibition of noxious TA temporal summation in animals
with contusion SCI was observed with albumin (p,0.001), oleic acid (OA, p,0.001) and albumin-oleic acid (Alb-OA, p,.001) when compared to the
group treated with saline alone (Sal, Fig. 2H). The stereoisomer complex albumin-elaidic acid (Alb-EA, 0.4/80 nanomoles) failed to inhibit flexor reflex
activity following contusion SCI (Fig. 2H). Statistical analysis was performed with a two-way ANOVA supported by the post-hoc Bonferronni test
compared to the SCI group treated with saline alone (*** - p,0.001).
doi:10.1371/journal.pone.0026107.g002
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different groups in response to the first stimulus (inset Fig. 2G) or
averaged over the second to seventh response (Fig. 2G) revealed no
treatment effect on general activity level, further supporting the use
of temporal summation as a measure of change in spinal central
sensitisation to noxious stimuli. In animals with SCI treated with
saline alone the temporal summation of the nociceptive TA flexor
reflex was observed up to a maximal value of 11366326% (average
of921685% during the 16 stimuli) when compared to the first reflex
response (Fig. 2H). In general temporal summation of the TA
noxious flexor reflex was modulated differently between the
experimental groups (F=42.69; d.f.=4,5; p,0.001). A similar level
of maximal TA temporal summation was observed in naı ¨ve rats
(13046564%, Fig. 2H). Post-hoc analysis revealed that temporal
summation of the TA nociceptive reflex was inhibited following
albumin (195613%; Tukey post-hoc test, p,0.001, q=14.36), oleic
acid alone (521644%; Tukey post-hoc test, p,0.001, q=7.91) or
albumin-oleic acid (434646%; Tukey post-hoc test, p,0.001,
q=9.62), when compared to the SCI control group treated with
saline alone (921685%, Fig. 2G). Interestingly animals treated with
albumin alone displayed greater inhibition of TA nociceptive reflex
temporal summation compared to those treated with albumin-oleic
acid (Tukey p,0.05, q=4.7).
When TA nociceptive reflex data were analyzed during the
early (2–7
th) or late (8–16
th) response (data not shown), intrathecal
administration of albumin alone, oleic acid alone and albumin-
oleic acid were shown to inhibit both the first and second phase of
temporal summation 28 days following contusion SCI when
compared to the group treated with saline alone (first phase:
10266117%; second phase: 9416125%). Specifically the first
phase of TA temporal summation was inhibited by Alb
(232624%, t=6.56, d.f.=94, p,0.001), OA (501640%,
t=4.03, d.f.=88, p,0.001) and Alb-OA (534679%, t=3.61,
d.f.=112, p,0.001) when compared to the saline treated group
with SCI. Similarly the second phase of TA temporal summation
was reduced by albumin (181614%, t=6.56, d.f.=94, p,0.001),
oleic acid (581670%, t=6.56, d.f.=133, p,0.05) and albumin-
oleic acid (403662%, t=4.18, d.f.=169, p,0.001).
Synergistic de novo phasic inhibition of TA reflex activity
across the iSCI with Alb-OA
Percutaneous high-frequency electrical conditioning stimulation
applied across the spinal cord above the contusion T9 SCI
revealed a strong phasic inhibition of nociceptive TA reflex
temporal summation following albumin-oleic acid treatment in
animals with SCI. Examination of the rectified TA reflex activity
recorded from animals with SCI and treated with albumin-oleic
acid before (Pre-Cond, Fig. 3C) and after (Post-Cond, Fig. 3C)
high-frequency electrical conditioning stimulation revealed this
strong inhibition of temporal summation (Fig. 3I). Synergistic
phasic inhibition of TA nociceptive reflex activity was evident in
animals treated with albumin-oleic acid from a peak of
6096212% to 3146115% (p,0.001, Fig. 3I) compared to no
effect measured following albumin (Fig. 3F) or oleic acid treatment
alone (Fig. 3G). Synergistic de novo phasic inhibition of TA
nociceptive reflex activity across the SCI following albumin-oleic
acid treatment was supported when compared to the presence of
normal phasic facilitation following conditioning electrical stimu-
lation in naı ¨ve animals without SCI from a peak of 13736511% to
17646173% (p,0.05, Fig. 3D).
The synergistic de novo phasic inhibition of TA reflex activity
following one month of albumin-oleic acid treatment was further
supported when data were analyzed for both the early and late
phase of temporal summation, where the second phase may
provide indirect evidence of descending modulatory mechanisms
(see methods, Fig. 4). Specifically albumin-oleic acid treatment
inhibited the first phase from 100615% to 4765% (t=3.43;
d.f.=20; p,0.01, Fig. 4C) and the second phase of TA
nociceptive reflex temporal summation from 75612% to
4765% (t=2.2; d.f.=20; p,0.05, Fig. 4C). The significant
decrease of the second phase of TA nociceptive reflex temporal
summation suggested that albumin-oleic acid promoted phasic
descending inhibitory control mechanisms (Fig. 4C). Furthermore
de novo phasic inhibition of TA temporal summation with Alb-OA
was shown to promote general antinociception when compared to
noxious reflex activity measured in naı ¨ve animals (Fig. 4D).
Potent synergistic increase in 5-HT innervation with
Alb-OA after iSCI
Detailed analysis of the volume of T9 contusion SCI in all the
experimental groups failed to identify general neuroprotection
either with albumin, oleic acid or with the albumin-oleic acid
complex. The volume of the contusion injury as a percentage of the
total possible volume measured in naı ¨ve animals was 30.563.4%
following SCI in the saline treated group. Similar values of SCI
contusion volumes were measured with treatment with albumin
alone (29.563.0%), oleic acid alone (28.962.1%), albumin-oleic
acid (28.962.4%) and albumin-elaidic acid (33.363.1%).
However immunohistochemical analysis revealed a potent
increase in 5-HT innervation density below the T9 contusion
SCI within the lumbar dorsal and ventral horn with albumin-oleic
acid treatment. Although 5-HT innervation density was difficult to
detect within the lumbar dorsal horn (Fig. 5A and 5B, see detailed
photographs in 5D–5F), Alb-OA treatment revealed a notable
generalized increase in lumbar dorsal horn 5-HT innervation
density below the SCI (Fig. 5C and 5F). An upregulation of
serotonin innervation with Alb-OA treatment was also evident in
the ventral horn (Fig. 5G–5H) and in the detailed photographs of
lamina VII (Fig. 5J–5L) and laminae IX (Fig. 5M–5O). Original
microphotographs of 5-HT immunohistochemistry are included
after Alb-OA treatment for lamina I–II (Fig. 5R) and lamina VII
(Fig. 5S) at 28 days after SCI.
Quantification of serotoninergic innervation density measured
below the SCI in animals treated with saline and normalised to the
naı ¨ve level (Fig. 5P dorsal horn: 1.0060.14, Fig. 5Q ventral horn:
1.0060.12) revealed non-significant decreases of 5-HT levels
within both the dorsal (0.6560.14, Fig. 5P) and ventral horn
(0.7660.10, Fig. 5Q). In general significant differences were
identified amongst all experimental groups within the dorsal
(F=6.79, d.f.=5, p,0.001) and ventral horn (F=6.96, d.f=5,
p,0.001). Only the albumin-oleic acid treatment significantly
increased the normalised 5-HT innervation density levels to a
remarkable 4.1761.09 fold (p,0.001, Fig. 5P) within the dorsal
horn and 2.2760.34 fold (p,0.001, Fig. 5Q) within the ventral
horn, when compared to animals treated with saline alone.
Further evidence for a neurotrophic effect of albumin-oleic acid
was evident by the significant difference between the observed
increase in 5-HT innervation density compared to animals treated
with albumin alone (dorsal horn: 1.2660.18, p,0.01; ventral
horn: 0.6560.03, p,0.001) or with oleic acid alone (dorsal horn:
1.5360.30, p,0.05; ventral horn: 1.0060.21, p,0.05).
The T9 spinal contusion injury increased microglia (OX-42)
density within both the dorsal laminae I/II (Fig. 6B) and lamina V
(Fig. 6E), accompanied by a generalized increase in the number of
cells with phosphorylated NMDA NR1 receptor within the dorsal
horn (Fig. 6J) compared to tissue from naı ¨ve animals (Fig. 6A,
6D, 6I). Importantly the albumin-oleic acid complex inhibited
microglial OX-42 reactivity (Fig. 6C and 6F) and the number of
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in naı ¨ve animals (Fig. 6K).
Spinal T9 contusion injury led to an increase in microglial OX-
42 area within the superficial (LI/II: naı ¨ve 25.163.2, contusion
81.560.18, p,0.001, Fig. 6G) and deep dorsal horn (LV: naı ¨ve
13.361.4, contusion 97.8624.3, p,0.001, Fig. 6H). Compared to
microglial reactivity following SCI, the OX-42 area decreased
within both the superficial (21.663.9, p,0.001, Fig. 6G) and deep
dorsal horn (32.664.80, p,0.01, Fig. 6H) following albumin-oleic
acid treatment.
When compared to naı ¨ve animals, an increase in the number of
pNR1-positive cells following SCI was observed within the
superficial dorsal horn from 66.9611.1 to 101.9610.1 (p,0.05,
Fig. 6L) and deep dorsal horn 110.068.3 to 147.368.1 (p,0.01,
Fig. 6M). Treatment with albumin-oleic acid reduced the number
of pNR1-positive cells compared to the SCI group treated with
saline alone within the superficial (38.262.6, p,0.001, Fig. 6L)
and deeper dorsal horn (69.264.5, p,0.001, Fig. 6M). Interest-
ingly within the deep dorsal horn, albumin-oleic acid treatment
decreased pNR1-positive cells to below that identified in naı ¨ve
levels (69.264.5 vs. 110.068.3, p,0.01, Fig. 6M), suggesting a
clear antinociceptive effect.
Discussion
The novel effect of intrathecal albumin, oleic acid and especially
Alb-OA treatment on spinal and descending inhibition of TA
nociceptive reflex activity and early recovery of voluntary motor
function following iSCI is described for the first time in this study,
and is supported by the simultaneous modulation of three spinal
cellular mechanisms at the lumbar level. These include reduction
of NR1 NMDA receptor phosphorylation, inhibition of microglial
reactivity and a strong increase in 5-HT levels to above normal
levels within the dorsal and ventral horn. The specific synergistic
effect of the putative neurotrophic factor Alb-OA on promotion of
tonic and de novo phasic descending inhibition of spinal noxious
reflex excitability across the iSCI is notable. In addition the
measurement of Tibialis Anterior reflex activity using standard
spinal and a newly developed translational measure of descending
function assures the clinical relevance of the effect of Alb-OA as a
novel neurotrophic factor in vivo following central neurotrauma.
The potentially safe clinical profile of this complex [50] and to the
possibility that specific SCI symptoms of spinal change in
nociceptive function and spasticity could be treated with Alb-OA
is discussed below.
Pleiotropic effect of Alb-OA on noxious central
sensitisation and paralysis after iSCI
Albumin comprises of about half of blood serum protein and
has multiple specific binding sites for fatty acids [23,51]. Motor
recovery and neuroprotection have been demonstrated with both
albumin [21] and omega 3 fatty acids following iSCI [22,49].
Although OA is a known neurotrophic factor in vitro [20], a
functional effect of systemic administration of this omega-9 fatty
acid has not been demonstrated alone [22], and is supported by
the poor motor recovery following SCI observed in our study. In
contrast inhibition of flexor reflex activity was identified
individually with either Alb or OA, as predicted by other studies
[21,52–54]. Surprisingly synergistic early motor recovery and de
novo phasic inhibition of spinal nociceptive reflex activity was
observed only when both molecules were combined, which
suggests that the neurotrophic effect of this complex in vivo is
likely to be mediated via collateral sprouting of residual descending
modulatory pathways after iSCI [37]. An in vitro study demon-
strates that extracellular Alb and OA are incorporated into
neurons leading to dendritic growth and GAP-43 upregulation
[20]. At the in vivo level CNS injury leads to SCD-1 upregulation,
the enzyme responsible for oleic acid synthesis [55], which is also
related to normal myelin production [56]. Another in vitro study
has demonstrated that oleic acid-mediated upregulation of GAP-
43 is synergistic with the neurotrophic factors NT3 and NT4/5
[57]. Interestingly the role of these factors have been related to the
prevention of corticospinal tract atrophy [58] and the promotion
of serotoninergic innervation below iSCI [59].
The application of the non-invasive electrical conditioning
protocol developed to indirectly assess the role of descending
pathways across the iSCI was adapted from Liu et al. (1998),
which examined long-term depression (LTD) of C-fibre-evoked
field potentials [47]. Interestingly in the original study LTD was
shown to convert to long-term potentiation when the spinal cord
was transected, suggesting that the activation of descending
inhibitory control systems maybe critical for the observation of
spinal reflex inhibition in vivo [47]. Although phasic descending of
noxious reflex excitability has been demonstrated in uninjured
animals with the application of other electrical conditioning
stimuli remote to the test site [34], this is the first time that this
technique has revealed descending modulatory system plasticity
following iSCI following treatment, although the role of altered
propriospinal system function through the iSCI cannot be
excluded [60,61].
Alb-OA modulates iSCI neuronal excitability,
neuroinflammation and serotonin neuroplasticity
Albumin-OA mediated a strong increase in serotonin innerva-
tion density within both the dorsal and ventral lumbar level, higher
than that observed following other experimental treatments
[37,62] or indeed to that found in uninjured spinal tissue. Oleic
acid is an allosteric factor for the 5-HT7A receptor [63], and this
receptor is present within the superficial dorsal horn [64] and
may play a role in analgesia [65]. As such tonic inhibition of
nociceptive TA reflex temporal summation could be mediated
via 5-HT7A receptor activation [66]. Although there are many 5-
HT receptor subtypes with mixed inhibitory and facilitatory
neuronal effects, enhanced neuroplasticity of residual descending
systems with a phenotypic shift from serotoninergic facilitation to
inhibition of spinal function [66] would be expected to overcome
Figure 3. Albumin-Oleic Acid Promotes De Novo Synergistic Descending Inhibition of Tibialis Anterior Reflex Activity after SCI.
Examination of rectified Tibialis Anterior (TA) electromyograhic reflex activity (Fig. 3A–3C) revealed strong inhibition of temporal summation in
animals with T9 spinal contusion (Cont) treated with albumin-oleic acid (Alb-OA, 0.4/80 nanomoles) following high-frequency conditioning
stimulation (Post-Cond) above the SCI when compared to the pre-conditioning (Pre-Cond) response (Fig. 3C, scale bar 10 mV/2.5 s). No inhibition was
observed either in naı ¨ve (Fig. 3A, scale bar 20 mV/2.5 s) or in animals with contusion SCI treated with saline alone (Fig. 3B, scale bar 20 mV/2.5 s).
Quantitative analysis of TA reflex temporal summation (Fig. 3D–3I) demonstrated a phasic facilitation in naı ¨ve animals following high-frequency
electrical conditioning (Fig. 3D), which was absent in the experimental SCI groups (Fig. 3E–3I). Indeed de novo synergistic phasic inhibition of TA reflex
activity mediated across the SCI was only promoted by treatment with albumin-oleic acid (Alb-OA, Fig. 3I, p,0.001), but not with albumin (Alb,
Fig. 3F), oleic acid (OA, Fig. 3G) or albumin-elaidic acid (Alb-EA, Fig. 3H). Statistical analysis was performed with a one-way ANOVA for each
experimental group (Fig. 3D–3I, * - p,0.05; *** - p,0.001).
doi:10.1371/journal.pone.0026107.g003
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iological mechanism of change in nociception [18] and motor
function [17] following SCI.
At the lumbar spinal level inhibition of nociceptive TA reflex
temporal summation with Alb-OA was reflected also by a decrease
in the number of lumbar dorsal horn neurons with phosphorylated
NR1 receptors. The NR1 NMDA receptor subtype is present
within the dorsal horn [67] and on motoneurones [68], and
specific variants of this receptor are upregulated after contusion
SCI [69]. Temporal summation of nociceptive flexor reflex activity
can be pharmacologically blocked with NMDA antagonists
following ischemic SCI [70], and NR1 phosphorylation is related
to central spinal sensitisation to noxious stimuli [71]. Importantly
the relationship between descending inhibitory systems and
reduction of pNR1 activation has been demonstrated recently
with the application of monoaminergic agonists following NMDA
administration [72], suggesting the hypothesis that increased
descending serotoninergic tract function promoted by Alb-OA
Figure 4. Albumin-Oleic Acid Promotes Phasic Inhibition of Early and Late Tibialis Anterior Reflex Activity following SCI. Analysis of
the first and second phase of Tibialis Anterior (TA) reflex temporal summation in naı ¨ve animals (Fig. 4A) and those with SCI 28 days after T9 spinal
contusion (Cont) revealed that the synergistic phasic inhibitory effect of Albumin-Oleic acid produced with the high-frequency electrical conditioning
stimulation when normalized to the first phase of the pre-conditioned response was present during both the early and late phases of temporal
summation (Fig. 4C), but not in the group treated with Saline (Sal, Fig. 4B) or in naı ¨ve animals (Fig. 4A). Furthermore activation of phasic inhibition of
absolute integrated TA reflex activity measured during both phases of temporal summation revealed that Alb-OA treatment significantly inhibited
nociceptive activity to below the normal value observed in naı ¨ve animals during the early phase (Fig. 4D). Statistical analysis was performed with a
one-way ANOVA supported by a post-hoc Bonferroni test (* - p,0.05; ** - p,0.01, ***-p,0.001).
doi:10.1371/journal.pone.0026107.g004
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excitability via control of the pNR1 NMDA receptor subtype
below the iSCI.
Albumin-OA treatment also strongly reduced microglia reac-
tivity within the lumbar dorsal horn following SCI. Microglia
activation has been identified up to several weeks following SCI in
humans [73] and is part of the normal inflammatory response
[74]. Furthermore microglia reactivity has been implicated in
central sensitisation to noxious stimuli [16] and in patients
following SCI with symptoms of spasticity [75]. Oleic acid inhibits
the induction of proinflammatory mediators, such as NF-kB,
within microglial cell culture [54], and so may have a direct effect
against neuroinflammation. In parallel with the hypothesis
suggested above for the interaction between descending seroto-
ninergic and spinal mechanisms of excitability modulated via
the pNR1 NMDA receptor, the application of noradrenergic
agonists such as clonidine has been shown to inhibit GFAP
upregulation, nuclear factor-kappa B activation, and p38 mitogen-
activated protein kinase induction following peripheral nerve
injury [76]. As such Albumin-OA complex treatment may control
spinal excitability following iSCI following descending 5-HT
inhibitory tract neuroplasticity, which in turn would inhibit
microglia reactivity and NMDA receptor phosphorylation follow-
ing iSCI.
Clinical significance of Alb-OA treatment for iSCI and
remaining key experiments
Simultaneous successful treatment of SCI central sensitisation to
noxious stimuli, spasticity, and paralysis below the injury depends
on the control of several spinal pathophysiological mechanisms
[2,77–80], which can be broadly grouped into processes of
neuronal excitability, neuroinflammation and plasticity of senso-
rimotor circuits following partial or complete damage to the spinal
cord [7–10]. Novel pleiotropic treatments are not only required to
modulate these basic mechanisms [9,11–13], but to target the most
debilitating symptoms of spasticity and pain [2,81,82], without
precipitating secondary effects of somnolence or fatigue [83–85].
Neurophysiological evidence for the modulation of non-invasive
translational measures of spinal nociceptive reflex activity such as
those used here, combined with immunohistochemical evidence
for the role of three cellular mechanisms of action related to the
control of spinal sensorimotor function, demonstrates that the Alb-
OA complex meets all of these criterion.
While Alb has a an established clinical safety profile [86], only
indirect evidence exists for OA as a non-toxic agent according to
one nutritional study of olive oil administration [50]. Importantly
in our study no change in feeding behaviour, body weight or
grooming was observed with Alb-OA treatment following iSCI.
Albumin most probably provides therapeutic benefits for spinal
cord injury when administered alone [21]. Indeed the replacement
of cerebrospinal fluid with 8% albumin following experimental
ischaemic experimental SCI can reduce motor deficits, although
this has been attributed mainly to reduction of intraspinal oedema
[87]. However evidence for direct penetrability of Alb-OA into the
spinal parenchyma should be addressed in future studies.
Functional motor recovery has been identified when Alb is
injected directly into the spinal tissue or via the intravenous route
[21], but careful analysis should be performed with FITC-albumin
injected via the intrathecal route which would address this
concern. Indeed a similar study has identified both grey and
white spinal matter labelling with FITC-albumin when adminis-
tered via the intravenous route, confirming penetration at least
into the intraspinal microcirculatory system [87]. Albumin is
commonly used a drug delivery system in the clinical setting [88]
and specific known binding sites with OA suggest a biological basis
for the synergistic action between both molecules observed in this
study [89]. As such drug delivery of OA across the blood brain
barrier could be mediated by albumin transcytosis [90,91],
followed by cellular uptake within the spinal parenchyma [19],
and synergistic modulation of sensorimotor function following
iSCI.
Of course several limitations regarding the preclinical develop-
ment and translational application of Alb-OA still remain,
including the possibility of its administration via the systemic
route and characterisation of the therapeutic window. General
neuroprotection following SCI was not observed with Alb-OA in
this study, in direct contrast to the effect of omega-3 fatty acids
such as docosahexanoic acid alone [22], or in combination
with albumin in a stroke model [92]. The neurotrophic effect
of Albumin-OA in vivo also needs to be addressed directly
through pharmacological blockade of the peroxisome pro-
liferator activated receptors, the role of which have been
highlighted in an in vitro study [93]. Finally, further evidence for
specific cellular in vivo mechanisms of action of Alb-OA should
now be extended with invasive neuroanatomical and neurophys-
iological techniques to further understand the role of Alb-OA on
both extrapyramidal and corticospinal descending control systems
across the iSCI.
Conclusion
The Albumin-Oleic acid complex is a new pharmacological
treatment strategy with pleiotropic functional effects for the
symptoms of paralysis, spasticity and change in spinal pain
processing following iSCI. Initial evidence of specific mechanisms
of action include the simultaneous tonic and de novo phasic
descending inhibition of spinal reflex excitability mediated by a
potent increase in lumbar 5-HT innervation, with a reduction in
NR1 NMDA receptor phosphorylation and microglial reactivity.
Neurotrophic enhancement of collateral sprouting of residual 5-
HT fibres across the iSCI has been demonstrated to mediate
locomotor recovery [38,39]. However the effective inhibition by
Alb-OA of a translational non-invasive measure of the most
debilitating symptoms of spasticity and change in spinal nocicep-
tion [81,82], while promoting residual voluntary motor function
below the lesion, represents an important clinical goal for subacute
rehabilitation of patients with iSCI.
Figure 5. Albumin-Oleic Acid Increases Serotonin (5-HT) Innervation to Above Normal Levels after SCI. Immunohistochemical images
revealed that 5-HT innervation density was increased within both the dorsal and ventral horn following Albumin-Oleic acid treatment (0.4/80
nanomoles, 5C and 5I, 10x) compared to either naı ¨ve animals (A and G, 10x) or those with SCI contusion (Cont) treated with saline alone (Sal, B and H,
10x). Detailed photographs of laminae I-II (D-F, note faint medial signal in D), lamina VII (J–L) and lamina IX (M–O) revealed the normal presence of 5-
HT fibres with varicosities (D, J, M), following SCI (E, K, N) and in animals with spinal T9 contusion with albumin-oleic acid treatment (F, L, O).
Quantification of the increase in lumbar 5-HT innervation levels below the SCI within the dorsal (P, p,0.001) or ventral horn (Q, p,0.001) following
Albumin-OA treatment (Alb-OA, 0.4/80 nanomoles) was observed, but not after saline (Sal), albumin (Alb), oleic acid (OA) or albumin-elaidic acid (Alb-
EA) administration. Statistical analysis was performed with a one-way ANOVA for each experimental group (P and Q, *** - p,0.001). Detailed original
examples of fluorescent images of 5-HT fibres within laminae I–II (R) and laminae VII (S) are included with Alb-OA treatment 28 days after T9 SCI.
doi:10.1371/journal.pone.0026107.g005
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